Publications by Ceke Hellström
Peer reviewed
Articles
[1]
D. R. Dou et al., "Xist ribonucleoproteins promote female sex-biased autoimmunity," Cell, vol. 187, no. 3, pp. 16-733, 2024.
[2]
J. Olofsson et al., "Array-Based Multiplex and High-Throughput Serology Assays," Methods in Molecular Biology, vol. 2628, pp. 535-553, 2023.
[3]
A. Notarnicola et al., "Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis," Annals of the Rheumatic Diseases, vol. 82, pp. 574-574, 2023.
[4]
C. Preger et al., "Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies," Journal of Autoimmunity, vol. 134, 2023.
[5]
S. Mravinacová et al., "A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies," New Biotechnology, vol. 66, pp. 46-52, 2022.
[6]
F. Marabita et al., "Article Multiomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health," CELL SYSTEMS, vol. 13, no. 3, pp. 241-255.e7, 2022.
[7]
M. Bronge et al., "Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis," Science Advances, vol. 8, no. 17, 2022.
[8]
S. Havervall et al., "Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19," Journal of Internal Medicine, vol. 291, no. 1, pp. 72-80, 2022.
[9]
S. Havervall et al., "SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection," PLOS ONE, vol. 17, no. 1, pp. e0262169-e0262169, 2022.
[10]
K. Healy et al., "Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals," MED, vol. 3, no. 2, pp. 137-153, 2022.
[11]
J. Dillner et al., "Antibodies to SARS-CoV-2 and risk of past or future sick leave," Scientific Reports, vol. 11, no. 1, 2021.
[12]
S. Havervall et al., "Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2," EBioMedicine, vol. 70, 2021.
[13]
C. Preger et al., "Autoantigenic Properties Indicated for the Entire Aminoacyl tRNA -Synthetase Family in Idiopathic Inflammatory Myopathies," Arthritis & Rheumatology, vol. 73, pp. 1-2, 2021.
[14]
J. Dillner et al., "High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers," The Journal of Infectious Diseases, vol. 224, no. 1, pp. 14-20, 2021.
[15]
P. San Segundo-Acosta et al., "Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers," Journal of Proteome Research, vol. 20, no. 11, pp. 5115-5130, 2021.
[16]
H. Alkharaan et al., "Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19 : A Complementary Approach to Population Surveys," Journal of Infectious Diseases, vol. 224, no. 3, pp. 407-414, 2021.
[17]
S. Hober et al., "Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay," Clinical & Translational Immunology (CTI), vol. 10, no. 7, 2021.
[18]
T. Abdellah et al., "Integration of molecular profiles in a longitudinal wellness profiling cohort," Nature Communications, vol. 11, no. 1, 2020.
[19]
A.-S. Rudberg et al., "SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.," Nature Communications, vol. 11, no. 1, 2020.
[20]
A. Notarnicola et al., "Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features," Arthritis & Rheumatology, vol. 71, 2019.
[21]
M. Neiman et al., "Individual and stable autoantibody repertoires in healthy individuals," Autoimmunity, vol. 52, no. 1, pp. 1-11, 2019.
[22]
K. Tengvall et al., "Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk," Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 34, pp. 16955-16960, 2019.
[23]
J. Frostegård et al., "Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus," Lupus, vol. 27, no. 10, pp. 1670-1678, 2018.
[24]
D. Djureinovic et al., "Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer," Lung Cancer, 2018.
[25]
L. Lourido et al., "Discovery of circulating proteins associated to knee radiographic osteoarthritis," Scientific Reports, vol. 7, 2017.
[26]
H. Idborg et al., "PROTEIN PROFILING IN PLASMA REVEALS MOLECULAR SUBGROUPS IN SYSTEMIC LUPUS ERYTHEMATOSUS," Annals of the Rheumatic Diseases, vol. 76, pp. A52-A52, 2017.
[27]
A. Zandian et al., "Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis," Translational Psychiatry, vol. 7, 2017.
[28]
A. Häggmark-Månberg et al., "Autoantibody targets in vaccine-associated narcolepsy," Autoimmunity, vol. 49, no. 6, pp. 421-433, 2016.
[29]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," New Biotechnology, vol. 33, no. 5, pp. 582-592, 2016.
[30]
J. C. ten Berge et al., "Serum Autoantibody Profiling of Patients with Paraneoplastic and Non-Paraneoplastic Autoimmune Retinopathy," PLOS ONE, vol. 11, no. 12, 2016.
Chapters in books
[31]
E. Pin et al., "Array-based profiling of proteins and autoantibody repertoires in CSF," in Cerebrospinal Fluid (CSF) Proteomics, : Humana Press Inc., 2019, pp. 303-318.
[32]
R. Sjöberg et al., "High-density antigen microarrays for the assessment of antibody selectivity and off-target binding," in Epitope Mapping Protocols, : Humana Press Inc., 2018, pp. 231-238.
[33]
C. Hellström et al., "High-density serum/plasma reverse phase protein arrays," in Serum/Plasma Proteomics, : Humana Press, 2017, pp. 229-238.
Non-peer reviewed
Articles
[34]
C. Preger et al., "Abundant autoantibody isotypes in idiopathic inflammatory myopathies," Annals of the Rheumatic Diseases, vol. 81, no. Suppl 1, pp. 242.2-243, 2022.
[35]
M. Rabenstein et al., "Humoral and cellular immune responses after SARSCoV-2-Vaccination in a Swedish cohort of persons with multiple sclerosis treated with disease modifying therapies," Multiple Sclerosis Journal, vol. 28, no. 3_SUPPL, pp. 103-104, 2022.
[36]
O. Thomas et al., "Re-visiting alpha beta-crystallin : EBNA1 antibody crossreactivity and CRYAB-specific T cell responses in multiple sclerosis," Multiple Sclerosis Journal, vol. 28, no. 3_SUPPL, pp. 233-234, 2022.
[37]
C. Preger et al., "Autoantigenic properties indicated for the entire aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies," Scandinavian Journal of Rheumatology, vol. 50, pp. 70-71, 2021.
[38]
M. Bronge et al., "T cell reactivity screening reveals four novel CNS autoantigens in multiple sclerosis," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 344-345, 2021.
[39]
C. Preger et al., "Characterization of anti-aminoacyl TRNA synthetase autoantibodies in patients with idiopathic inflammatory myopathies," Annals of the Rheumatic Diseases, vol. 79, pp. 1084-1085, 2020.
[40]
J. Frostegard et al., "Autoantibody Profiling Reveals Four Protein Candidate Autoantigens Associated With Sle and One of Them With Atherosclerosis and Echolucent Plaques," Circulation, vol. 138, 2018.
[41]
T. Olsson et al., "Molecular mimicry between the autoantigen Anoctamin 2 and Epstein Barr virus nuclear antigen 1 associates with increased risk for multiple sclerosis," Multiple Sclerosis Journal, vol. 24, pp. 64-64, 2018.
[42]
M. Persson et al., "Searching for Novel Autoantibodies with Clinical Relevance in Psychiatric Disorders," Schizophrenia Bulletin, vol. 44, pp. S120-S121, 2018.
[43]
E. Wiklundh et al., "The Autoimmune Repertoire in Idiopathic Pulmonary Fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 197, 2018.
[44]
D. Djureinovic et al., "Autoantibody Profiles of Cancer-Testis Genes in Non-Small Cell Lung Cancer," Journal of Thoracic Oncology, vol. 12, no. 11, pp. S2002-S2002, 2017.
[45]
A. Notarnicola et al., "NEW AUTOIMMUNE TARGETS IN IDIOPATHIC INFLAMMATORY MYOPATHIES - AN ANTIGEN BEAD ARRAY APPROACH," Annals of the Rheumatic Diseases, vol. 76, pp. 626-626, 2017.
[46]
A. Notarnicola et al., "ANALYSIS OF THE AUTOANTIBODY REPERTOIRE IN IDIOPATHIC INFLAMMATORY MYOPATHIES USING ANTIGEN BEAD ARRAY," Annals of the Rheumatic Diseases, vol. 74, pp. 174-174, 2015.
Other
[47]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," (Manuscript).
Latest sync with DiVA:
2024-07-17 11:01:41